2. Academic Validation
  3. Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease

Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease

  • Sci Adv. 2026 Jan 30;12(5):eadt2804. doi: 10.1126/sciadv.adt2804.
Zhen Zhang 1,  Richard J Lobb 1,  Paul Tooney 2 3 4,  Jing Wang 1 5,  Rebecca Lane 1,  Quan Zhou 1,  Xueming Niu 1,  Sam Faulkner 2 3,  Oun Al-Iedani 2,  Bryan W Day 6 7 8,  Simon Puttick 9,  Stephen Rose 9,  Mike Fay 3 10 11,  Matt Trau 1 12
Affiliations

Affiliations

  • 1 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.
  • 2 School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
  • 3 Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, Newcastle, NSW 2308, Australia.
  • 4 Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia.
  • 5 Key Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
  • 6 Cancer Research Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, QLD 4006, Australia.
  • 7 School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.
  • 8 School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • 9 AdvanCell Pty Ltd., Queensland Centre for Advanced Technologies, Brisbane, QLD 4069, Australia.
  • 10 School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
  • 11 GenesisCare, Lake Macquarie Private Hospital, Newcastle, NSW 2290, Australia.
  • 12 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
PMID: 41616062 DOI: 10.1126/sciadv.adt2804
Abstract

Assessing therapeutic response in glioblastoma (GBM) is a major factor limiting the clinical development of effective therapies. The intracranial location limits serial biopsies and only provides an intermittent view of the tumor molecular profile from the initial resection. Liquid biopsy techniques, specifically small extracellular vesicle (sEV) analysis, have the potential to overcome these limitations by providing a window into the brain using peripheral blood. To address the need for monitoring tumor evolution and therapeutic resistance, we developed a GBM biomarker panel (ATPase subunit beta-2, excitatory Amino acid Transporter 2, CD24, CD44, CD133, and epidermal growth factor receptor) for multiplexed profiling of sEVs using an advanced GBM Extracellular Vesicle Monitoring Phenotypic Analyzer Chip. We successfully tracked patient response to treatment by monitoring changes in glioma stem cell markers on circulating sEVs. We propose that these results provide a strong rationale for using GBM sEVs as a serial monitoring tool in the future clinical management of patients with GBM.

Figures
Products